Complete Genomics is making headlines. Read the most recent news about Complete Genomics and advances in complete human genome sequencing.
Complete Genomics Inc. (NASDAQ: GNOM) announced today that it has sequenced the genomes of 600 individuals from 20 Mexican-American families from San Antonio in what is thought to be the largest whole genome sequencing family study conducted to date
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, today announced that it has signed four new distributor agreements with well-established Asia-Pacific life sciences companies
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) today announced financial results for its quarter ended March 31, 2012.
>> read more
Complete Genomics, Inc. (Nasdaq: GNOM) will release its first quarter 2012 financial results at approximately 1:00 p.m. PDT on May 7, 2012.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) has begun accepting DNA samples derived from human saliva.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), the whole human genome sequencing company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2011.
>> read moreComplete Genomics, Inc. (Nasdaq:GNOM) will release its fourth quarter and fiscal year 2011 financial results after markets close on March 8, 2012.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that members of its management team will present at the following conferences in March
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, today announced the formation of its Genomic Medicine Advisory Board (GMAB).
>> read moreComplete Genomics, Inc. (NASDAQ: GNOM) announced today that the journal Nature has published a neuroblastoma study conducted using the company’s high-depth whole human genome sequencing service.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) announced today that Genome Research has published a paper it co-authored describing the effects of hepatitis B virus (HBV) integration into the genomes of liver cancer patients.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) today announced that the company will be included in MIT’s Technology Review TR50, an annual list of the 50 most innovative technology companies in the world. It is the third-consecutive year that Complete Genomics has been named to the list.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, today introduced its Genomic Discovery Software Partners Program.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) announced today that it has been selected by Mayo Clinic’s Center for Individualized Medicine to provide outsourced whole human genome sequencing. Mayo Clinic researchers will now be able to employ Complete Genomics’ sequencing service for some of its large-scale whole genome sequencing projects.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) announced today that the Journal of Computational Biology has published online the company’s paper describing some of the computational methods that enable it to produce highly-accurate whole human genome sequencing data.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), today announced that the company delivered approximately 3,000 genomes to its customers in 2011 and is entering 2012 with contracts for approximately 5,800 genomes.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that Ajay Bansal, Chief Financial Officer of Complete Genomics will present at the Oppenheimer 22nd Annual Healthcare Conference at 11:25 a.m. ET on Wednesday, December 14, 2011.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), the whole human genome sequencing company, today announced its financial results for the quarter ended September 30, 2011.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) will release its third quarter 2011 financial results after markets close on November 7, 2011.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that Dr. Cliff Reid, chairman, president, and CEO of Complete Genomics will present at the following conferences in November
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, introduced its new Cancer Sequencing Service today at the International Congress of Human Genetics (ICHG) and American Society of Human Genetics (ASHG) Annual Meeting in Montréal.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, and the not-for-profit Scripps Health system today announced a major collaboration that will help further the Wellderly Study, a landmark scientific research initiative aimed at unlocking the genetic secrets of lifelong health.
>> read moreMOUNTAIN VIEW, Calif., and FALLS CHURCH, Va. – Complete Genomics Inc. (NASDAQ: GNOM), a complete human genome sequencing company, and Inova Health System, a not-for-profit healthcare system based in Northern Virginia, today announced additional details about their partnership.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that members of its management team will present at the following conferences in September
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the complete human genome sequencing company, today announced it has appointed Keith Raffel as chief commercial officer (CCO) and Dr. Jill Hagenkord as chief medical officer (CMO).
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the complete human genome sequencing company, today announced additional details about the option that SAIC-Frederick Inc. has exercised to have Complete Genomics sequence the DNA from more than 500 pediatric cancer cases.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) today announced its financial results for the quarter ended June 30, 2011.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) will release its second quarter 2011 financial results after markets close on Wednesday August 3, 2011.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), a complete human genome sequencing company, today announced that it is introducing a new cancer grant program.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that members of its management team will present at the following conferences in June
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) announced the closing of its underwritten public offering of 6,325,000 shares of its common stock at $12.50 per share.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at $12.50 per share. Complete Genomics has granted the underwriters a 30-day option to purchase up to 825,000 additional shares
>> read more